A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies

Trial Profile

A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Ulocuplumab (Primary) ; Bendamustine; Cytarabine; Etoposide; Mitoxantrone; Rituximab
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top